Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Open-Label Study of VX-765 in Muckle-Wells Syndrome
2004-000283-27Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2005
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belnacasan in Muckle-Wells syndrome (MWS), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability, Anti-inflammatory effects and 1 more. Started Feb 2005; status: completed.
02
Drugs
belnacasan
03
Conditions
Muckle-Wells syndrome (MWS)
Beyond the preview
Go deeper on 2004-000283-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000283-27.